Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025. Eli Lilly and Company (NYSE:LLY) ...

Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

Eli Lilly is moving to deepen its bet on inflammatory disease, striking a deal to acquire biotech player Ventyx Biosciences ...

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...

A deal for Ventyx would help Lilly compete in the promising space. If Ventyx’s experimental pills pan out, they would add to ...

Eli Lilly and Company and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in ...

A report in the Wall Street Journal, citing people familiar with the matter, suggested an announcement of a transaction could ...

Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than $1 billion, the Wall Street Journal reported on ...

Eli Lilly has announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, a biopharmaceutical ...

Eli Lilly and Company has entered a definitive agreement to acquire Ventyx Biosciences Inc., a San Diego-based clinical-stage ...

The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...